Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration

The profound pharmacokinetic variability of linezolid given twice daily at 600aEuroSmg iv to patients on renal replacement therapy indicates that the EUCAST breakpoint of 2aEuroSmg/L is unlikely to be achieved.Few data are available to guide linezolid dosing during renal replacement therapy. The objective of this study was to compare the population pharmacokinetics of linezolid during continuous venovenous haemofiltration (CVVHF, 30 mL/kg/h) and continuous venovenous haemodiafiltration (CVVHDF, 15 mL/kg/haEuroS+aEuroS15 mL/kg/h)